Kato, TerufumiTerufumiKatoCHIH-HSIN YANGAhn, Myung-JuMyung-JuAhnSakai, HiroshiHiroshiSakaiMorise, MasahiroMasahiroMoriseChen, Yuh-MinYuh-MinChenHan, Ji-YounJi-YounHanYang, Jin-JiJin-JiYangZhao, JunJunZhaoHsia, Te-ChunTe-ChunHsiaBerghoff, KarinKarinBerghoffBruns, RolfRolfBrunsVioix, HeleneHeleneVioixLang, SimoneSimoneLangJohne, AndreasAndreasJohneLe, XiuningXiuningLePaik, Paul KPaul KPaik2024-07-092024-07-092024-06-01https://scholars.lib.ntu.edu.tw/handle/123456789/719673Tepotinib, a MET inhibitor approved for the treatment of MET exon 14 (METex14) skipping NSCLC, demonstrated durable clinical activity in VISION (Cohort A + C; N = 313): objective response rate (ORR) 51.4% (95% CI: 45.8, 57.1); median duration of response (mDOR) 18.0 months (95% CI: 12.4, 46.4). We report outcomes in Asian patients from VISION (Cohort A + C) (cut-off: November 20, 2022).Patients with advanced METex14 skipping NSCLC, detected by liquid or tissue biopsy, received tepotinib 500 mg (450 mg active moiety) once daily.objective response (RECIST 1.1) by independent review. Secondary endpoints included: DOR, progression-free survival (PFS), overall survival (OS), safety, and health-related quality of life (HRQoL).Across treatment lines in 106 Asian patients (39.6% female, 43.4% smoking history, 79.2% adenocarcinoma, 47.2% treatment-naive), ORR was 56.6% (95% CI: 46.6, 66.2), mDOR 18.5 months (10.4, ne), mPFS 13.8 months (10.8, 22.0), and mOS 25.5 months (19.3, 36.4). Consistent efficacy observed, regardless of baseline characteristics. HRQoL remained stable during treatment. Treatment-related adverse events (TRAEs) occurred in 95.3% of patients (39.6% Grade ≥3). Most common TRAEs: peripheral edema (62.3%), creatinine increase (38.7%).Tepotinib demonstrated robust and durable efficacy, with a manageable safety profile, in Asian patients with METex14 skipping NSCLC.NCT02864992.en[SDGs]SDG3journal article10.1038/s41416-024-02615-938575731